A new trading day began on May 23, 2023, with Neurocrine Biosciences Inc. (NASDAQ: NBIX) stock priced at $93.69, up 0.15% from the previous day of trading. During the day, the shares moved up to $94.045 and dropped to $92.895 before settling in for the closing price of $93.50. NBIX’s price has ranged from $84.42 to $129.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 55.90%. Meanwhile, its annual earnings per share averaged 70.70%. With a float of $94.93 million, this company’s outstanding shares have now reached $97.10 million.
Let’s determine the extent of company efficiency that accounts for 1200 employees. In terms of profitability, gross margin is +97.43, operating margin of +16.84, and the pretax margin is +14.37.
Neurocrine Biosciences Inc. (NBIX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – Specialty & Generic Industry. The insider ownership of Neurocrine Biosciences Inc. is 0.30%, while institutional ownership is 96.90%. The most recent insider transaction that took place on May 01, was worth 1,184,049. In this transaction Chief Human Resources Officer of this company sold 11,397 shares at a rate of $103.89, taking the stock ownership to the 16,169 shares. Before that another transaction happened on May 01, when Company’s Director sold 4,300 for $101.43, making the entire transaction worth $436,135. This insider now owns 42,785 shares in total.
Neurocrine Biosciences Inc. (NBIX) Recent Fiscal highlights
In its latest quarterly report, released on 3/30/2023, the company reported earnings of -$0.79 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a net margin of +10.38 while generating a return on equity of 10.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 70.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.80% during the next five years compared to 24.30% growth over the previous five years of trading.
Neurocrine Biosciences Inc. (NASDAQ: NBIX) Trading Performance Indicators
Here are Neurocrine Biosciences Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.76. Likewise, its price to free cash flow for the trailing twelve months is 39.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.61, a number that is poised to hit 0.76 in the next quarter and is forecasted to reach 4.60 in one year’s time.
Technical Analysis of Neurocrine Biosciences Inc. (NBIX)
Looking closely at Neurocrine Biosciences Inc. (NASDAQ: NBIX), its last 5-days average volume was 0.84 million, which is a jump from its year-to-date volume of 0.78 million. As of the previous 9 days, the stock’s Stochastic %D was 12.67%. Additionally, its Average True Range was 2.24.
During the past 100 days, Neurocrine Biosciences Inc.’s (NBIX) raw stochastic average was set at 2.33%, which indicates a significant decrease from 10.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 24.11% in the past 14 days, which was lower than the 30.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $99.15, while its 200-day Moving Average is $107.69. However, in the short run, Neurocrine Biosciences Inc.’s stock first resistance to watch stands at $94.16. Second resistance stands at $94.68. The third major resistance level sits at $95.31. If the price goes on to break the first support level at $93.01, it is likely to go to the next support level at $92.38. Now, if the price goes above the second support level, the third support stands at $91.86.
Neurocrine Biosciences Inc. (NASDAQ: NBIX) Key Stats
With a market capitalization of 9.22 billion, the company has a total of 97,575K Shares Outstanding. Currently, annual sales are 1,489 M while annual income is 154,500 K. The company’s previous quarter sales were 420,400 K while its latest quarter income was -76,600 K.
